Amcinonide NDC 73308-407

NDC codes

FDA NDC Directory

Product NDC (as listed)73308-407Labeler and product segments. Claims need a package NDC.

Product NDC at billing width73308-0407Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
73308-407-60	73308040760	1 TUBE in 1 CARTON (73308-407-60) / 60 g in 1 TUBEMarketed from May 1, 2023

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Amcinonide
Generic name (nonproprietary): amcinonide
Active ingredients: Amcinonide — 1 mg/g
Dosage form: Ointment
Route: Topical
Labeler: Ayurax, LLC
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 076096
Marketing start: May 1, 2023
Listing expires: Dec 31, 2026
Other FDA classes: Corticosteroid Hormone Receptor Agonists (Mechanism)
Identifiers: Product ID 73308-407_86f4ed99-b557-44f7-966d-4f187e89784cSPL ID 86f4ed99-b557-44f7-966d-4f187e89784cSPL set ID 83da75e7-e182-4a6c-ac0f-50d99971ebdeRxCUI 197328UNII 423W026MA9UPC 0373308407605
Pharmacologic class: Corticosteroid

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Topical products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N473308040760 followed by a unit qualifier and the quantity

Package 73308-0407-60. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Oct 6, 2025.

Indications (excerpt from the label)

INDICATIONS AND USAGE: Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)